| Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication S Burugu, K Asleh-Aburaya, TO Nielsen Breast cancer 24, 3-15, 2017 | 240 | 2017 |
| Advances in sarcoma diagnostics and treatment AR Dancsok, K Asleh-Aburaya, TO Nielsen Oncotarget 8 (4), 7068, 2017 | 122 | 2017 |
| Proteomic analysis of archival breast cancer clinical specimens identifies biological subtypes with distinct survival outcomes K Asleh, GL Negri, SE Spencer Miko, S Colborne, CS Hughes, XQ Wang, ... Nature Communications 13 (1), 896, 2022 | 73 | 2022 |
| Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications K Asleh, N Riaz, TO Nielsen Journal of Experimental & Clinical Cancer Research 41 (1), 265, 2022 | 64 | 2022 |
| Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor BS Sheffield, Z Kos, K Asleh-Aburaya, XQ Wang, S Leung, D Gao, J Won, ... Breast cancer research and treatment 155, 483-490, 2016 | 38 | 2016 |
| Molecular subtyping of mammary‐like adenocarcinoma of the vulva shows molecular similarity to breast carcinomas B Tessier‐Cloutier, K Asleh‐Aburaya, V Shah, WG McCluggage, A Tinker, ... Histopathology 71 (3), 446-452, 2017 | 27 | 2017 |
| Predictive biomarkers for adjuvant capecitabine benefit in early-stage triple-negative breast cancer in the FinXX clinical trial K Asleh, HA Brauer, A Sullivan, S Lauttia, H Lindman, TO Nielsen, ... Clinical Cancer Research 26 (11), 2603-2614, 2020 | 24 | 2020 |
| Phospho-Ser784-VCP Is required for DNA damage response and is associated with poor prognosis of chemotherapy-treated breast cancer C Zhu, A Rogers, K Asleh, J Won, D Gao, S Leung, S Li, KR Vij, J Zhu, ... Cell Reports 31 (10), 2020 | 23 | 2020 |
| Differential expression and prognostic relevance of autophagy-related markers ATG4B, GABARAP, and LC3B in breast cancer S Bortnik, B Tessier-Cloutier, S Leung, J Xu, K Asleh, S Burugu, J Magrill, ... Breast Cancer Research and Treatment 183, 525-547, 2020 | 20 | 2020 |
| Basal biomarkers nestin and INPP4b identify intrinsic subtypes accurately in breast cancers that are weakly positive for oestrogen receptor K Asleh‐Aburaya, BS Sheffield, Z Kos, JR Won, XQ Wang, D Gao, ... Histopathology 70 (2), 185-194, 2017 | 20 | 2017 |
| Nestin expression in breast cancer: association with prognosis and subtype on 3641 cases with long-term follow-up K Asleh, JR Won, D Gao, KD Voduc, TO Nielsen Breast cancer research and treatment 168, 107-115, 2018 | 17 | 2018 |
| Clinical and molecular characteristics of triple-negative breast cancer patients in Northern Israel: single center experience K Asleh-Aburaya, G Fried Springerplus 4, 1-7, 2015 | 13 | 2015 |
| Association between low admission Norton scale scores and postoperative complications after elective THA in elderly patients K Asleh, R Sever, S Hilu, R Ron, A Gold, M Aharon, M Salai, D Justo Orthopedics 35 (9), e1302-e1306, 2012 | 12 | 2012 |
| Extracellular vesicle-based liquid biopsy biomarkers and their application in precision immuno-oncology K Asleh, V Dery, C Taylor, M Davey, MA Djeungoue-Petga, RJ Ouellette Biomarker Research 11 (1), 99, 2023 | 11 | 2023 |
| The immune microenvironment and relation to outcome in patients with advanced breast cancer treated with docetaxel with or without gemcitabine ES Stovgaard, K Asleh, N Riaz, S Leung, D Gao, LB Nielsen, ... Oncoimmunology 10 (1), 1924492, 2021 | 10 | 2021 |
| Basal biomarkers nestin and INPP4B predict gemcitabine benefit in metastatic breast cancer: samples from the phase III SBG0102 clinical trial K Asleh, S Lyck Carstensen, CL Tykjær Jørgensen, S Burugu, D Gao, ... International journal of cancer 144 (10), 2578-2586, 2019 | 10 | 2019 |
| Triple-negative PAM50 non-basal breast cancer subtype predicts benefit from extended adjuvant capecitabine K Asleh, A Lluch, A Goytain, C Barrios, XQ Wang, L Torrecillas, D Gao, ... Clinical Cancer Research 29 (2), 389-400, 2023 | 8 | 2023 |
| SRY‐box transcription factor 10 is a highly specific biomarker of basal‐like breast cancer KA Klaric, N Riaz, K Asleh, XQ Wang, T Atalla, S Strickland, TO Nielsen, ... Histopathology 80 (3), 589-597, 2022 | 7 | 2022 |
| Proteomics-derived basal biomarker DNA-PKcs is associated with intrinsic subtype and long-term clinical outcomes in breast cancer K Asleh, N Riaz, AS Cheng, D Gao, SCY Leung, M Anurag, TO Nielsen NPJ Breast Cancer 7 (1), 114, 2021 | 6 | 2021 |
| Role of intratumoral NK cells in triple-negative breast cancer in the FinXX trial and Mayo Clinic cohort. S Chumsri, JM Carter, Y Ma, D Hinerfeld, HA Brauer, S Warren, ... Journal of Clinical Oncology 38 (15_suppl), 510-510, 2020 | 5 | 2020 |
